EUCTR2018-004024-11-ES进行中（未招募）1 期
An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •The subject will not be considered eligible for the study without meeting all of the criteria below.
- •1. Male, aged 18 to 75 years at the time of screening.
- •2. Established severe or moderately severe hemophilia B (plasma FIX activity
- •= 2% measured following = 5 half-lives of most recent exposure to exogenous FIX)
- •and either = 3 hemorrhages per year requiring treatment with exogenous FIX or use
- •of prophylactic therapy.
- •3. History of > 50 exposure days to exogenously administered FIX concentrates or
- •cryoprecipitates.
- •4. Sexually active men must agree to use barrier contraception (combination of a condom and spermicide) or limit sexual intercourse to post-menopausal, surgically sterilized, or contraception-practicing partners for a minimum of 6 months after administration of SHP648, or until SHP648 genomes are no longer detected in the semen (whichever is sooner).
- •5. Signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 19
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •The subject will be excluded from the study if any of the following exclusion criteria are met.
- •1. Bleeding disorder(s) other than hemophilia B.
- •2. Documented laboratory evidence of having developed inhibitors (= 0.6 BU on any single test) to FIX proteins at any time.
- •3. Documented prior allergic reaction to any FIX product.
- •4. Anti-AAV8 neutralizing antibody titer = 1:5.
- •5. Known hypersensitivity to prednisolone or prednisone, or to any of the excipients.
- •6. Having a disease in which treatment with prednisolone or prednisone is not tolerated
- •(including, but not limited to osteoporosis with vertebral fractures, severe labile
- •hypertension, and brittle diabetes).
- •7. Evidence of markers of potential underlying risk for autoimmune mediated hepatic disease:
- •a. Anti-smooth muscle antibody (ASMA) titer = 1:40. Values of 1:31 to 1:39 will be
- •flagged as possibly abnormal and the Investigator and Medical Monitor will evaluate the subject for eligibility.
- •b. Elevated anti-liver-kidney microsomal antibody type 1 (LKM1) titers.
- •c. Total IgG > 1.5x ULN.
- •d. Antinuclear antibody (ANA) titer > 1:320 OR ANA titer > 1:80 if demonstrated
- •concurrently with ALT that is > ULN.
- •8. Active Hepatitis C: As indicated by detectable HCV RNA by PCR.
- •9. Hepatitis B: If surface HBV antigen is positive.
- •10. Receiving chronic systemic antiviral and/or interferon therapy within 4 weeks prior to enrollment.
- •11. Clinically significant infections (e.g., systemic fungal infections) requiring systemic treatment.
- •12. Known immune disorder (including myeloma and lymphoma).
- •13. Concurrent chemotherapy or biological therapy for treatment of neoplastic disease or other disorders.
- •14. An absolute neutrophil count < 1000 cells/mm3.
- •15. Markers of hepatic inflammation or cirrhosis as evidenced by 1 or more of the following:
- •a. Platelet count < 150,000/µL.
- •b. Albumin = 3.5 g/dL.
- •c. Total bilirubin > 1.5x ULN and direct bilirubin = 0.5 mg/dL.
- •d. ALT or AST > 1.0x ULN.
- •e. Alkaline phosphatase > 2.0x ULN.
- •f. History of liver biopsy or imaging indicating moderate or severe fibrosis
- •(Metavir staging of F2 or greater).
- •g. History of ascites, varices, variceal hemorrhage, or hepatic encephalopathy.
- •h. FibroSURE Score = 0.4.
- •i. Prothrombin time INR = 1.4.
- •16. Serum creatinine > 1.5 mg/dL.
- •17. HIV if CD4+ cell count =200 mm3 and/or viral load >20 copies/mL.
- •18. Urine protein > 30 mg/dL.
- •19. Body mass index > 38.
- •20. Orthopedic or other major surgery planned within 6 months after enrollment.
- •21. Acute or chronic disease that, in the opinion of the Investigator, would adversely affect subject safety or compliance or interpretation of study results.
- •22. Received an AAV vector previously or any other gene transfer agent in the previous 12 months prior to Study Day 0.
- •23. Significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, congestive heart failure, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease).
- •24. History of arterial or venous thrombosis / thromboembolism, or a known pro-thrombotic condition.
- •25. Recent history of psychiatric illness or cognitive dysfunction (including drug or alcohol abuse) that, in the opinion of the Investigator, is likely to impair subject’s ability to comply with protocol mandated procedures.
- •26. Participation in another study involved with an investigational agent.
- •27. Subject is family member or employ
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B SubjectsHemophilia B is a X-linked recessive bleeding disorder caused by mutations in the gene encoding clotting factor IX (FIX) that result in disruption of the normal clotting pathway. Hemophilia B affects 1 in 25,000 male births. Disease severity correlates directly with the concentration of functional FIX protein in the plasma. Severe disease is characterized as having <1% of normal plasma levels of FIX (100% = 1 IU activity/mL or approximately 5000 ng protein/mL).MedDRA version: 20.0Level: LLTClassification code 10060614Term: Hemophilia B (Factor IX)System Organ Class: 100000004850EUCTR2018-004024-11-FRBaxalta Innovations GmbH21
进行中（未招募）
1 期
A Phase 1/2 study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B SubjectsEUCTR2018-004024-11-HUBaxalta Innovations GmbH21
进行中（未招募）
1 期
A Phase 1/2 study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B SubjectsEUCTR2018-004024-11-DEBaxalta Innovations GmbH21
进行中（未招募）
1 期
A Phase 1/2 study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B SubjectsHemophilia B is a X-linked recessive bleeding disorder caused by mutations in the gene encoding clotting factor IX (FIX) that result in disruption of the normal clotting pathway. Hemophilia B affects 1 in 25,000 male births. Disease severity correlates directly with the concentration of functional FIX protein in the plasma. Severe disease is characterized as having <1% of normal plasma levels of FIX (100% = 1 IU activity/mL or approximately 5000 ng protein/mL).MedDRA version: 20.0Level: LLTClassification code 10060614Term: Hemophilia B (Factor IX)System Organ Class: 100000004850EUCTR2018-004024-11-ATBaxalta Innovations GmbH21
进行中（未招募）
1 期
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML).Relapsed or refractory AML, AML secondary to myeloproliferative neoplasms (MPN), and JAK2 mutationpositive AML.MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2019-001201-24-ESKartos Therapeutics, Inc.135